SYMBIOTEC Share Price Target 2030

CAGR-based price projection for Symbiotec Pharmalab Limited (SYMBIOTEC) targeting 2030, derived from official NSE exchange closing prices.

Bear Case (3.7% CAGR)
Rs 1,383
2030 Target
Base Case (9.1% CAGR)
Rs 1,700
2030 Target
Bull Case (24.8% CAGR)
Rs 2,910
2030 Target

Current Market Snapshot

CMP: Rs 1,198.00
52W High: Rs 1,198.00
52W Low: Rs 1,003.35
1Y CAGR: 19.1%
3Y CAGR: 9.1%

Year-by-Year Price Projection

YearBear CaseBase CaseBull Case
2027 Rs 1,242 Rs 1,307 Rs 1,496
2028 Rs 1,287 Rs 1,427 Rs 1,867
2029 Rs 1,334 Rs 1,557 Rs 2,331
2030 Rs 1,383 Rs 1,700 Rs 2,910

Other SYMBIOTEC Price Targets

2025 2026 2027 2028 2035 2040 2050

Frequently Asked Questions

What is the SYMBIOTEC share price target for 2030?

Based on historical growth analysis, the SYMBIOTEC share price target for 2030 ranges from Rs 1,383 (conservative) to Rs 1,700 (base case) to Rs 2,910 (optimistic). These projections are based on trailing CAGR and should not be treated as guaranteed outcomes.

What is the current share price of SYMBIOTEC?

The current market price of SYMBIOTEC (Symbiotec Pharmalab Limited) is Rs 1,198.00. The 52-week high is Rs 1,198.00 and 52-week low is Rs 1,003.35.

Is SYMBIOTEC a good stock to buy for the long term?

Long-term investment decisions depend on individual risk tolerance, financial goals, and portfolio diversification. Examine the company's fundamentals, debt-to-equity ratio, promoter holding, and competitive positioning within its sector. BrokerLens provides data-driven analysis; consult a SEBI-registered financial advisor before investing.

What methodology does BrokerLens use for SYMBIOTEC price targets?

BrokerLens computes price targets using historical Compound Annual Growth Rate (CAGR) derived from official NSE closing prices. Three scenarios are modeled: Bear (conservative at 3.7% CAGR), Base (9.1% CAGR), and Bull (optimistic at 24.8% CAGR). These are statistical projections, not guaranteed forecasts.

Disclaimer: Share price targets on BrokerLens are statistical CAGR projections based on historical NSE closing prices. They are NOT guaranteed outcomes, investment advice, or analyst recommendations. Past performance does not guarantee future results. Consult a SEBI-registered investment advisor before making investment decisions. Mutual fund and equity investments are subject to market risks.